Uterine cancer remains the most common and second most deadly gynecological cancer in the United States, with an estimated 61,880 new cases and 12,160 deaths per year (Siegel et al., 2019). Those with early stage disease have a good prognosis of a 95% 5-year survival rate compared to only 17% of women with advanced staged disease (Makker et al., 2017). Furthermore, there has been a significant in- crease in the number of endometrial cancer-associated deaths over the past 20 years (Makker et al., 2017). Recently, novel treatments such as immunotherapies directed by biomarkers have received significant at- tention in gynecologic oncology (Garcia and Ring, 2018). Pem- brolizumab, a programmed cell death protein-1 (PD-1) signal pathway inhibitor, was approved by the FDA in May 2017 for malignancies characterized by microsatellite instability (MSI) or mismatch repair (MMR) deficiency, agnostic of tissue type (“Pembrolizumab Prescribing Information,” 2019). Given its recent approval, there have been few reports that have described the long-term response to pembrolizumab in endometrial cancer (Le et al., 2017; Ott et al., 2017; Marabelle et al., 2020). Here, we present two cases with metastatic, chemotherapy-re- sistant endometrial cancers treated with pembrolizumab who have achieved long-term durable responses.
展开▼
